FCCC LOGO Faculty Publications
Berger AC , Garcia M , Hoffman JP , Regine WF , Abrams RA , Safran H , Konski A , Benson AB , MacDonald J , Willett CG
Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704
Journal of Clinical Oncology. 2008 Dec;26(36) :5918-5922
Back to previous list
Abstract
Purpose CA 19-9 is an important tumor marker in patients with pancreatic adenocarcinoma. A secondary end point of Radiation Therapy Oncology Group trial 9704 was prospective evaluation of the ability of postresectional CA 19-9 to predict survival. Methods CA 19-9 expression was analyzed as a dichotomized variable ( < 180 v >= 180) or ( <= 90 v > 90). Cox proportional hazards models were utilized to identify the impact of CA 19-9 expression on overall survival ( OS). Actuarial estimates for OS were calculated using Kaplan-Meier methods. Results Three hundred eighty-five patients patients had assessable CA 19-9 levels. The majority had a CA 19-9 level lower than 180 or <= 90 ( n = 220 and 200, respectively), while 34% were Lewis Antigen negative and 33 ( 9%) and 53 ( 14%) patients had levels higher than 180 and higher than 90. When CA 19-9 was analyzed as a dichotomized variable, there was a significant survival difference favoring patients with CA 19-9 lower than 180 ( hazard ratio [ HR], 3.53; P < .0001). This corresponds to a 72% reduction in the risk of death for patients with a CA 19-9 lower than 180. This was also true for patients with CA 19-9 <= 90 ( HR, 3.4; P < .0001). Multivariate analyses confirmed that CA 19-9, when analyzed as both a continuous and a dichotomized variable, is a highly significant predictor of OS in patients with resected pancreatic cancer. Conclusion To our knowledge, this is the first phase III trial to perform prospective analysis of CA 19-9 levels in patients treated with adjuvant chemoradiotherapy. It definitively confirms the prognostic importance of postresectional CA 19-9 levels after surgery with curative intent in patients with pancreatic cancer.
Notes
ISI Document Delivery No.: 385WF Berger, Adam C. Garcia, Miguel, Jr. Hoffman, John P. Regine, William F. Abrams, Ross A. Safran, Howard Konski, Andre Benson, Alan B., III MacDonald, John Willett, Christopher G. AMER SOC CLINICAL ONCOLOGY